10-Q: TherapeuticsMD Reports Q2 Profit, Revenue Surge

TherapeuticsMD, a pharmaceutical royalty company, reported a significant increase in Q2 2025 license revenue and a return to net income from continuing operations, despite ongoing legal disputes and going concern doubts.

Summary

• TherapeuticsMD has fully transitioned into a pharmaceutical royalty company, no longer engaged in research, development, or commercial operations.
• License revenue for Q2 2025 increased significantly to $952 thousand, up from $234 thousand in Q2 2024, primarily from the Mayne License Agreement.
• For the six months ended June 30, 2025, license revenue was $1,345 thousand, compared to $547 thousand for the same period in 2024.
• The company reported net income of $551 thousand, or $0.05 per basic and diluted common share, for Q2 2025, a significant improvement from a net loss of $1,090 thousand, or $0.09 per share, in Q2 2024.
• Net loss for the first six months of 2025 was reduced to $102 thousand, or $0.01 per share, from $1,824 thousand, or $0.16 per share, in the first six months of 2024.
• Operating expenses decreased by 45.5% in Q2 2025 to $1,647 thousand, largely due to the absence of a $1,261 thousand impairment charge recognized in Q2 2024.
• Cash and cash equivalents increased to $6,069 thousand as of June 30, 2025, up from $5,059 thousand at December 31, 2024.
• The company is involved in ongoing legal disputes with Mayne Pharma regarding net working capital allowances and indemnification demands, with lawsuits filed by both parties in April and May 2025.
• Patent infringement lawsuits against Teva Pharmaceuticals USA, Inc. and Sun Pharma Inc. concerning generic versions of IMVEXXY are ongoing, with patents expiring in 2032 or 2033.
• Management has identified substantial doubt about the company's ability to continue as a going concern for the next twelve months, citing potential Mayne Pharma sales declines, adverse lawsuit outcomes, and financing challenges.

Sentiment

Score: 6

Explanation: The company shows significant financial improvement with a return to net income in Q2 and substantial revenue growth from its royalty model. However, the explicit 'going concern' doubt, coupled with ongoing, material legal disputes with its primary licensee and patent challenges from generic competitors, introduces considerable uncertainty and risk, tempering the positive financial results.

Positives

• License revenue for Q2 2025 increased by $718 thousand (306.8%) to $952 thousand compared to Q2 2024.
• Shifted from a net loss of $1,090 thousand in Q2 2024 to a net income of $551 thousand in Q2 2025.
• Reduced net loss for the first six months of 2025 to $102 thousand from $1,824 thousand in the prior year period.
• Operating expenses significantly decreased by $1,376 thousand (45.5%) in Q2 2025 due to the absence of a prior year impairment charge.
• Cash and cash equivalents increased by $1,010 thousand to $6,069 thousand as of June 30, 2025.
• Net cash provided by continuing operating activities was $1,080 thousand for the first six months of 2025.

Negatives

• The company continues to report a net loss for the six months ended June 30, 2025, totaling $102 thousand.
• Total assets slightly decreased to $38,504 thousand as of June 30, 2025, from $38,822 thousand at December 31, 2024.
• Total stockholders' equity slightly decreased to $27,292 thousand as of June 30, 2025, from $27,370 thousand at December 31, 2024.
• Other income, net, decreased to $1,240 thousand in Q2 2025 from $1,739 thousand in Q2 2024, primarily due to a gain on early sublease termination recognized in 2024.
• Net cash provided by continuing operating activities decreased to $1,080 thousand for the first six months of 2025 from $1,224 thousand in the prior year period, primarily due to lower non-cash adjustments.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months due to liquidity requirements.
• Ongoing legal disputes with Mayne Pharma regarding net working capital allowances (payer rebates, wholesale distributor fees, returns) could result in unforeseen losses.
• Mayne Pharma's potential sale to Cosette Pharmaceuticals, Inc. could impact sales of Licensed Products and royalty revenue.
• Patent infringement lawsuits against Teva Pharmaceuticals USA, Inc. and Sun Pharma Inc. for generic IMVEXXY could lead to generic competition and reduced royalty rates (from 8.0%/7.5% to 2.0%).
• The need to raise additional capital through equity or debt financing could dilute existing stockholders' ownership interests.
• Terms of new securities issued for capital raises may include liquidation or other preferences that adversely affect existing stockholders' rights.
• Inability to obtain additional financing could force the company to discontinue or curtail business operations, sell assets at unfavorable prices, or merge unfavorably.
• Supply chain issues related to third-party contract manufacturers could impact product availability and royalty generation.
• The outcome of the Mayne Lawsuits is uncertain, and the company cannot reasonably estimate a range of loss, potentially leading to material changes in estimated amounts owed or due.

Future Outlook

The company's primary source of revenue is from royalties on licensed products. It may need to raise additional capital through equity or debt financing to fund operations until it becomes cash flow positive. The ability to sell equity securities may be limited by market conditions and available authorized shares, potentially diluting existing stockholders. The potential impact of Mayne Pharma's sales, the outcome of ongoing lawsuits, and future financing success, combined with capital market uncertainties, raise substantial doubt about the company's ability to continue as a going concern for the next twelve months.

Management Comments

• Our Chief Executive Officer concluded that our disclosure controls and procedures as of the end of the period covered by this 10-Q Report were effective in providing reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial and Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure.

Industry Context

TherapeuticsMD has completed its strategic transformation from a women's healthcare product developer and commercializer to a pharmaceutical royalty company. This shift aligns with a trend where companies monetize their intellectual property through licensing agreements, reducing operational overhead and focusing on royalty streams. The company's portfolio of women's health products (IMVEXXY, BIJUVA, ANNOVERA, prenatal vitamins) remains relevant in the pharmaceutical market, but its direct involvement is now limited to managing license agreements and collecting royalties. The ongoing patent litigation against generic manufacturers highlights the persistent challenge of intellectual property protection in the pharmaceutical industry, even for royalty-focused entities.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Patent infringement lawsuit against Teva Pharmaceuticals USA, Inc. (filed April 2020) regarding a generic version of IMVEXXY. The statutory stay was lifted in November 2024. Patents expire in 2032 or 2033.
• Patent infringement lawsuit against Sun Pharma Inc. (filed July 2024) regarding a generic version of IMVEXXY. Patents expire in 2032 or 2033.
• Lawsuit filed by TherapeuticsMD against Mayne Pharma (April 8, 2025) in the U.S. District Court for the District of Delaware, seeking damages for breach of contract, breach of implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to net working capital allowances and Mayne Pharma's actions.
• Amended complaint filed by TherapeuticsMD against Mayne Pharma on June 20, 2025.
• Motion to dismiss filed by Mayne Pharma against TherapeuticsMD's lawsuit on July 22, 2025.
• Lawsuit filed by Mayne Pharma against TherapeuticsMD (May 30, 2025) in the U.S. District Court for the District of Delaware, seeking damages for breach of contract and fraudulent inducement related to the Transaction Agreement.
• Motion to dismiss filed by TherapeuticsMD against Mayne Pharma's countersuit on July 28, 2025.
• Mayne Pharma is responsible for all enforcement and costs of patent litigation related to the licensed products.

Related Party Transactions

• Justin Roberts, a director, is a Partner of Rubric Capital Management LP and has elected not to receive compensation for his director service.
• Entered into Subscription Agreements with Rubric Capital Management LP on July 29, 2022, September 30, 2022, October 28, 2022, and May 1, 2023.
• Redeemed all 29,000 outstanding shares of Series A Preferred Stock previously issued to affiliates of Rubric Capital Management LP on December 30, 2022, at a purchase price of $1,333 per share, and paid approximately $3.0 million as a make-whole payment.
• Issued and sold 312,525 shares of common stock to Rubric Capital Management LP on June 29, 2023, for gross proceeds of $1.15 million.
• Rubric Capital Management LP drew down an additional 877,192 shares of common stock on November 15, 2023, for gross proceeds of $2.0 million. No drawdowns occurred in the first six months of 2025 or 2024.

Stakeholder Impact

• Shareholders face potential dilution from future equity capital raises and uncertainty regarding the outcome of significant legal disputes with Mayne Pharma.
• Employees: The company has only one full-time employee (CEO) after its business transformation, indicating minimal direct impact on a large employee base.
• Customers (indirectly, through licensees): Continued availability of IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamins depends on the commercialization efforts and supply chains managed by licensees like Mayne Pharma, Knight, and Theramex.
• Suppliers: The company relies on third-party contract manufacturers for its licensed products, and supply chain issues could impact royalty revenue.
• Creditors: The 'going concern' doubt and potential need for additional financing could affect the company's creditworthiness and ability to meet future obligations.

Next Steps

• Resolution of the Mayne Lawsuits regarding net working capital allowances and indemnification demands.
• Continued defense of IMVEXXY patents against generic challenges from Teva Pharmaceuticals USA, Inc. and Sun Pharma Inc.
• Potential pursuit of additional equity and debt financing to address liquidity needs and achieve cash flow positivity.
• Evaluation of the impact of new accounting standards (ASU 2024-03 and ASU 2023-09) on future financial reporting disclosures.

Key Dates

Recommendation

While TherapeuticsMD has shown significant financial improvement, including a return to net income in Q2 2025 and substantial revenue growth from its royalty model, the company explicitly states 'substantial doubt' about its ability to continue as a going concern. This fundamental risk, coupled with ongoing, material legal disputes with its primary licensee (Mayne Pharma) and persistent patent litigation against generic competitors, creates significant uncertainty. The potential for further dilution from future capital raises also weighs on shareholder value. Given the improved financial performance but severe underlying risks, a 'hold' recommendation is appropriate for a seasoned investor, suggesting caution and monitoring of the legal and liquidity situations before making further investment decisions.

Keywords

TherapeuticsMD, TXMD, pharmaceutical royalty, SEC filing, 10-Q, Q2 earnings, license revenue, net income, going concern, Mayne Pharma, IMVEXXY, BIJUVA, ANNOVERA, patent litigation, capital raise, women's healthcare